Solid Biosciences (SLDB)
(Delayed Data from NSDQ)
$8.98 USD
+0.44 (5.15%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $8.98 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SLDB 8.98 +0.44(5.15%)
Will SLDB be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for SLDB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SLDB
Solid Biosciences (SLDB) Falls Despite FDA Rare Tag for DMD Drug
Beat the Market Like Zacks: Walmart, Novo Nordisk, Procter & Gamble in Focus
SLDB: What are Zacks experts saying now?
Zacks Private Portfolio Services
REGENXBIO (RGNX) Soars 15% on Interim Data From DMD Study
Biotech Stock Roundup: VRTX/CRSP Gene Therapy Label Expansion, ALLK Falls on Update
Solid Biosciences' (SLDB) DMD Drug Gets Orphan Tag, Stock Up
Other News for SLDB
Edgewise gets EU orphan drug status for muscular dystrophy drug
Buy Solid Biosciences: Unpacking Its Main Value Driver
British billionaire fined $5M, sentenced to 3 years probation for insider trading
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences gets FDA rare pediatric disease status for DMD therapy